A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine

Summary

The study is an open-label, randomized,2-period, single dose, crossover study in 8 healthy male/female volunteers. Subjects will be randomized to the following sequences: (A) Period 1: KT110 - wash-out period - Period 2: Alpress and Periactin marketed tablets ; Or (B) Period 1: Alpress and Periactin marketed tablets - wash-out period - Period 2: KT110

Timeline

Start

2024-04-23

Primary completion

2024-07-31

Completion

2024-12-31

Drugs

Indications